Pharmacogenetics of toxic epidermal necrolysis

Bibliography

• Gomes ER, Demoly P. Epidemiology of hypersensitivity drug reactions. Curr Opin Allergy Clin Immunol 2005;5(4):309-16
   PubMedGoogle Scholar
• Rzany B, Mockenhaupt M, Baur S, Epidemiology of erythema exsudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990-1992): structure and results of a population-based registry. J Clin Epidemiol 1996;49(7):769-73
   PubMedGoogle Scholar
• Auquier-Dunant A, Mockenhaupt M, Naldi L, Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Arch Dermatol 2002;138(8):1019-24
   PubMedGoogle Scholar
• Wolf R, Orion E, Marcos B, Matz H. Life-threatening acute adverse cutaneous drug reactions. Clin Dermatol 2005;23(2):171-81
   PubMedGoogle Scholar
• Fagot JP, Mockenhaupt M, Bouwes-Bavinck JN, Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. AIDS 2001;15(14):1843-8
   PubMedGoogle Scholar
• Mockenhaupt M, Viboud C, Dunant A, Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol 2008;128(1):35-44
   PubMedGoogle Scholar
• Halevy S, Ghislain PD, Mockenhaupt M, Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol 2008;58(1):25-32
   PubMedGoogle Scholar
• Bastuji-Garin S, Rzany B, Stern RS, Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 1993;129(1):92-6
   PubMedGoogle Scholar
• French LE. Toxic epidermal necrolysis and Stevens Johnson syndrome: our current understanding. Allergol Int 2006;55(1):9-16
   PubMedGoogle Scholar
• Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994;331(19):1272-85
   PubMed Web of Science ®Google Scholar
• Roujeau JC, Guillaume JC, Fabre JP, Toxic epidermal necrolysis (Lyell syndrome). Incidence and drug etiology in France, 1981-1985. Arch Dermatol 1990;126(1):37-42
   PubMedGoogle Scholar
• Guillaume JC, Roujeau JC, Revuz J, The culprit drugs in 87 cases of toxic epidermal necrolysis (Lyell's syndrome). Arch Dermatol 1987;123(9):1166-70
   PubMedGoogle Scholar
• McIvor RA, Zaidi J, Peters WJ, Hyland RH. Acute and chronic respiratory complications of toxic epidermal necrolysis. J Burn Care Rehabil 1996;17(3):237-40
   PubMedGoogle Scholar
• Sugimoto Y, Mizutani H, Sato T, Toxic epidermal necrolysis with severe gastrointestinal mucosal cell death: a patient who excreted long tubes of dead intestinal epithelium. J Dermatol 1998;25(8):533-8
   PubMedGoogle Scholar
• Herman TE, Kushner DC, Cleveland RH. Esophageal stricture secondary to drug-induced toxic epidermal necrolysis. Pediatr Radiol 1984;14(6):439-40
   PubMedGoogle Scholar
• Roujeau JC, Chosidow O, Saiag P, Guillaume JC. Toxic epidermal necrolysis (Lyell syndrome). J Am Acad Dermatol 1990;23(6 Pt 1):1039-58
   PubMedGoogle Scholar
• Klein SM, Khan MA. Hepatitis, toxic epidermal necrolysis and pancreatitis in association with sulindac therapy. J Rheumatol 1983;10(3):512-3
   PubMedGoogle Scholar
• Edwards SG, Hubbard V, Aylett S, Wren D. Concordance of primary generalised epilepsy and carbamazepine hypersensitivity in monozygotic twins. Postgrad Med J 1999;75(889):680-1
   PubMedGoogle Scholar
• Mondino BJ, Brown SI, Biglan AW. HLA antigens in Stevens-Johnson syndrome with ocular involvement. Arch Ophthalmol 1982;100(9):1453-4
   PubMedGoogle Scholar
• Power WJ, Saidman SL, Zhang DS, HLA typing in patients with ocular manifestations of Stevens-Johnson syndrome. Ophthalmology 1996;103(9):1406-9
   PubMedGoogle Scholar
• Roujeau JC, Huynh TN, Bracq C, Genetic susceptibility to toxic epidermal necrolysis. Arch Dermatol 1987;123(9):1171-3
   PubMedGoogle Scholar
• Roujeau JC, Bracq C, Huyn NT, HLA phenotypes and bullous cutaneous reactions to drugs. Tissue Antigens 1986;28(4):251-4
   PubMedGoogle Scholar
• Shirato S, Kagaya F, Suzuki Y, Joukou S. Stevens-Johnson syndrome induced by methazolamide treatment. Arch Ophthalmol 1997;115(4):550-3
   PubMedGoogle Scholar
• Pirmohamed M, Park BK. Cytochrome P450 enzyme polymorphisms and adverse drug reactions. Toxicology 2003;192(1):23-32
   PubMed Web of Science ®Google Scholar
• Mockenhaupt M, Messenheimer J, Tennis P, Schlingmann J. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics. Neurology 2005;64(7):1134-8
   PubMedGoogle Scholar
• Chung WH, Hung SI, Hong HS, Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004;428(6982):486
   PubMed Web of Science ®Google Scholar
• Hung SI, Chung WH, Jee SH, Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet Genomics 2006;16(4):297-306
   PubMedGoogle Scholar
• Man CB, Kwan P, Baum L, Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia 2007;48(5):1015-8
   PubMedGoogle Scholar
• Locharernkul C, Loplumlert J, Limotai C, Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population. Epilepsia 2008;49(12):2087-91
   PubMedGoogle Scholar
• Lonjou C, Thomas L, Borot N, A marker for Stevens-Johnson syndrome: ethnicity matters. Pharmacogenomics J 2006;6(4):265-8
   PubMedGoogle Scholar
• Kaniwa N, Saito Y, Aihara M, HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics 2008;9(11):1617-22
   PubMedGoogle Scholar
• Ueta M, Sotozono C, Tokunaga K, Strong association between HLA-A*0206 and Stevens-Johnson syndrome in the Japanese. Am J Ophthalmol 2007;143(2):367-8
   PubMedGoogle Scholar
• Ueta M, Sotozono C, Inatomi T, Association of IL4R polymorphisms with Stevens-Johnson syndrome. J Allergy Clin Immunol 2007;120(6):1457-9
   PubMedGoogle Scholar
• Ueta M, Sotozono C, Inatomi T, Toll-like receptor 3 gene polymorphisms in Japanese patients with Stevens-Johnson syndrome. Br J Ophthalmol 2007;91(7):962-5
   PubMedGoogle Scholar
• Ueta M, Sotozono C, Inatomi T, Association of Fas Ligand gene polymorphism with Stevens-Johnson syndrome. Br J Ophthalmol 2008;92(7):989-91
   PubMedGoogle Scholar
• Alfirevic A, Jorgensen AL, Williamson PR, HLA-B locus in Caucasian patients with carbamazepine hypersensitivity. Pharmacogenomics 2006;7(6):813-8
   PubMedGoogle Scholar
• Lonjou C, Borot N, Sekula P, A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics 2008;18(2):99-107
   PubMedGoogle Scholar
• Pirmohamed M, Arbuckle JB, Bowman CE, Investigation into the multidimensional genetic basis of drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics 2007;8(12):1661-91
   PubMedGoogle Scholar
• Daar AS, Singer PA. Pharmacogenetics and geographical ancestry: implications for drug development and global health. Nat Rev Genet 2005;6(3):241-6
   PubMedGoogle Scholar
• Hoa BK, Hang NT, Kashiwase K, HLA-A, -B, -C, -DRB1 and -DQB1 alleles and haplotypes in the Kinh population in Vietnam. Tissue Antigens 2008;71(2):127-34
   PubMedGoogle Scholar
• Tang TF, Hou L, Chen M, HLA haplotypes in Singapore: a study of mothers and their cord blood units. Hum Immunol 2007;68(5):430-8
   PubMedGoogle Scholar
• Romano A, Gueant-Rodriguez RM, Viola M, Cross-reactivity among drugs: clinical problems. Toxicology 2005;209(2):169-79
   PubMedGoogle Scholar
• Romano A, Pettinato R, Andriolo M, Hypersensitivity to aromatic anticonvulsants: in vivo and in vitro cross-reactivity studies. Curr Pharm Des 2006;12(26):3373-81
   PubMedGoogle Scholar
• Hirsch LJ, Arif H, Nahm EA, Cross-sensitivity of skin rashes with antiepileptic drug use. Neurology 2008;71(19):1527-34
   PubMedGoogle Scholar
• Alvestad S, Lydersen S, Brodtkorb E. Cross-reactivity pattern of rash from current aromatic antiepileptic drugs. Epilepsy Res 2008;80(2-3):194-200
   PubMedGoogle Scholar
• Seitz CS, Pfeuffer P, Raith P, Anticonvulsant hypersensitivity syndrome: cross-reactivity with tricyclic antidepressant agents. Ann Allergy Asthma Immunol 2006;97(5):698-702
   PubMedGoogle Scholar
• Chen YC, Chu CY, Hsiao CH. Oxcarbazepine-induced Stevens-Johnson syndrome in a patient with HLA-B*1502 genotype. J Eur Acad Dermatol Venereol 2009;23(6):702-3
   PubMedGoogle Scholar
• Gogtay NJ, Bavdekar SB, Kshirsagar NA. Anticonvulsant hypersensitivity syndrome: a review. Expert Opin Drug Saf 2005;4(3):571-81
   PubMedGoogle Scholar
• Mallal S, Nolan D, Witt C, Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002;359(9308):727-32
   PubMedGoogle Scholar
• Hetherington S, Hughes AR, Mosteller M, Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 2002;359(9312):1121-2
   PubMedGoogle Scholar
• Hughes AR, Mosteller M, Bansal AT, Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations. Pharmacogenomics 2004;5(2):203-11
   PubMedGoogle Scholar
• Saag M, Balu R, Phillips E, High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. Clin Infect Dis 2008;46(7):1111-8
   PubMedGoogle Scholar
• Hung SI, Chung WH, Liou LB, HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA 2005;102(11):4134-9
   PubMedGoogle Scholar
• Dainichi T, Uchi H, Moroi Y, Furue M. Stevens-Johnson syndrome, drug-induced hypersensitivity syndrome and toxic epidermal necrolysis caused by allopurinol in patients with a common HLA allele: what causes the diversity? Dermatology 2007;215(1):86-8
   PubMedGoogle Scholar
• Tassaneeyakul W, Jantararoungtong T, Chen P, Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population. Pharmacogenet Genomics 2009;19(9):704-9
   PubMedGoogle Scholar
• Ferrell PB Jr, McLeod HL. Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations. Pharmacogenomics 2008;9(10):1543-6
   PubMedGoogle Scholar
• Chung WH, Hung SI, Yang JY, Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat Med 2008;14(12):1343-50
   PubMedGoogle Scholar
• Wu Y, Sanderson JP, Farrell J, Activation of T cells by carbamazepine and carbamazepine metabolites. J Allergy Clin Immunol 2006;118(1):233-41
   PubMedGoogle Scholar
• Pichler WJ, Beeler A, Keller M, Pharmacological interaction of drugs with immune receptors: the p-i concept. Allergol Int 2006;55(1):17-25
   PubMedGoogle Scholar
• Yang CW, Hung SI, Juo CG, HLA-B*1502-bound peptides: implications for the pathogenesis of carbamazepine-induced Stevens-Johnson syndrome. J Allergy Clin Immunol 2007;120(4):870-7
   PubMedGoogle Scholar
• Klein TE, Altman RB, Eriksson N, Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009;360(8):753-64
   PubMedGoogle Scholar